Epratuzumab, an anti-CD22 B cell depleting therapy studied in SLE patients had a positive effect on the systemic activity of SLE patients with Sjögren syndrome in a post-hoc analysis of EMBODY trial [337]. The gene discussed is CD22; the disease is systemic lupus erythematosus.